Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adri M Durant

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Urology|November 16, 2023
AUTHOR REPLYAdri M Durant, Gwen M Grimsby
Urologic Oncology|September 17, 2024
Testicular cancer malpractice trendsAdri M Durant, Connor J Mayes, Mark D Tyson
Urology|October 18, 2023
Greater Obstetric Barriers for Female Urologists Compared to Peer-PhysiciansAdri M Durant, Emily A Reeson, Gwen M Grimsby
Current Oncology Reports|April 30, 2025
Current State of Bladder Preservation in High Grade Non-Muscle Invasive Bladder Cancer and Localized Muscle Invasive Bladder CancerSwati Popli, Adri M Durant, Mark Tyson, et al.
American Journal of Surgery|October 25, 2024
A survey of parental leave for female physicians reveals dissatisfaction and inadequaciesBrielle V Ochoa, Adri M Durant, Kathleen van Leeuwen, et al.
Clinical Genitourinary Cancer|July 7, 2022
BCG Administration after Prior Radiation Treatment for Prostate CancerAdri M Durant, Yu-Hui Chang, Kassem S Faraj, et al.
Bladder Cancer (Amsterdam, Netherlands)|March 4, 2025
Repeat TURBT in large volume high-grade non-invasive bladder cancerAdri M Durant, Mimi Nguyen, Mouneeb M Choudry, et al.
International Urology and Nephrology|June 20, 2020
Hemostatic agent use during partial nephrectomy: trends, outcomes, and associated costsAdri M Durant, Erik Lehman, Haley Robyak, et al.
Urologic Oncology|October 18, 2023
Bacillus Calmette-Guerin (BCG) therapy is safe and effective in non-muscle invasive bladder cancer (NMIBC) patients with immunomodulating conditionsAdri M Durant, Mouneeb M Choudry, Grace Madura, et al.
The Canadian Journal of Urology|August 15, 2022
A comparison of naloxegol versus alvimopan at the time of cystectomy and urinary diversionKassem S Faraj, Weslyn Bunn, Adri M Durant, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Urology|November 16, 2023
AUTHOR REPLYAdri M Durant, Gwen M Grimsby
Urologic Oncology|September 17, 2024
Testicular cancer malpractice trendsAdri M Durant, Connor J Mayes, Mark D Tyson
Urology|October 18, 2023
Greater Obstetric Barriers for Female Urologists Compared to Peer-PhysiciansAdri M Durant, Emily A Reeson, Gwen M Grimsby
Current Oncology Reports|April 30, 2025
Current State of Bladder Preservation in High Grade Non-Muscle Invasive Bladder Cancer and Localized Muscle Invasive Bladder CancerSwati Popli, Adri M Durant, Mark Tyson, et al.
American Journal of Surgery|October 25, 2024
A survey of parental leave for female physicians reveals dissatisfaction and inadequaciesBrielle V Ochoa, Adri M Durant, Kathleen van Leeuwen, et al.
Clinical Genitourinary Cancer|July 7, 2022
BCG Administration after Prior Radiation Treatment for Prostate CancerAdri M Durant, Yu-Hui Chang, Kassem S Faraj, et al.
Bladder Cancer (Amsterdam, Netherlands)|March 4, 2025
Repeat TURBT in large volume high-grade non-invasive bladder cancerAdri M Durant, Mimi Nguyen, Mouneeb M Choudry, et al.
International Urology and Nephrology|June 20, 2020
Hemostatic agent use during partial nephrectomy: trends, outcomes, and associated costsAdri M Durant, Erik Lehman, Haley Robyak, et al.
Urologic Oncology|October 18, 2023
Bacillus Calmette-Guerin (BCG) therapy is safe and effective in non-muscle invasive bladder cancer (NMIBC) patients with immunomodulating conditionsAdri M Durant, Mouneeb M Choudry, Grace Madura, et al.
The Canadian Journal of Urology|August 15, 2022
A comparison of naloxegol versus alvimopan at the time of cystectomy and urinary diversionKassem S Faraj, Weslyn Bunn, Adri M Durant, et al.
Pageof 3